Drug intelligence / Profile preview

paracetamol + guaifenesin + phenylephrine

Development stage
Phase 3
Lead developer
Kenvue
Modality
Small Molecules
Administration
Oral
01

Overview

Vicks Active SymptoMax Plus is a multi-ingredient pharmaceutical product formulated for the symptomatic relief of the common cold and influenza. It is a combination of three active ingredients: paracetamol (acetaminophen), guaifenesin, and phenylephrine hydrochloride. Paracetamol serves as an analgesic and antipyretic, reducing pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Guaifenesin acts as an expectorant, increasing the volume and reducing the viscosity of secretions in the respiratory tract to facilitate mucus clearance. Phenylephrine hydrochloride is a sympathomimetic decongestant that functions as a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction in the nasal mucosa to alleviate congestion. The product is typically developed as a powder for oral solution, intended for rapid absorption and relief of symptoms such as headache, sore throat, nasal congestion, and productive cough.

Brand names
Vicks Active SymptoMax Plus
Other names
Vicks Active SymptoMax Plus Powder for Oral Solution
02

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on paracetamol + guaifenesin + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + guaifenesin + phenylephrine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call